K-RAS and EGFR in Lung Cancer

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

NCT00831454 ·Status: COMPLETED

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

NCT02293733 ·Status: COMPLETED

EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA

NCT02975752 ·Status: COMPLETED

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

NCT00898924 ·Status: COMPLETED

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

NCT02771314 ·Status: UNKNOWN ·Phase: PHASE2

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

NCT01255150 ·Status: COMPLETED

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

NCT03562819 ·Status: COMPLETED

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

NCT01382992 ·Status: UNKNOWN

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

NCT04912687 ·Status: COMPLETED ·Phase: NA

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

NCT04640870 ·Status: COMPLETED

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

NCT05127382 ·Status: UNKNOWN

INHERIT EGFR - Studying Germline EGFR Mutations

NCT01754025 ·Status: ACTIVE_NOT_RECRUITING

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

NCT03519958 ·Status: WITHDRAWN

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NCT01776684 ·Status: UNKNOWN ·Phase: NA

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

NCT01697163 ·Status: UNKNOWN

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

NCT00997230 ·Status: COMPLETED

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

NCT04742192 ·Status: COMPLETED

NGS Genome Analysis in Personalisation of Lung Cancer Treatment

NCT02281214 ·Status: COMPLETED ·Phase: NA

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

NCT04222335 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

NCT04122833 ·Status: UNKNOWN

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

NCT06595498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

NCT01525199 ·Status: COMPLETED

Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study

NCT00717002 ·Status: COMPLETED